Building on these findings, Yan et al. reported that HHLA2 was present in 77.17% of pancreatic ductal adenocarcinoma (PDAC) cases and that its higher expression was correlated with better post-surgical survival rates (Yan et al. 2019). Here, HHLA2 is linked to pancreatic ductal adenocarcinoma.